Latest close: a new 52-week lowSep 8, 2026what changed →
On our screens:Stocks with no debtCheap stocks by free cash flow yieldQuality compoundersQuality at a reasonable price
Is the price fair?
What ANIP's price assumes
ANI Pharmaceuticals, Inc. trades at 17.8× earnings against 24.3× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
17.8
Trailing P/E · Drug Manufacturers - Specialty & Generic median 24.3 · cheaper than the typical name in its group
- Price / sales
- 1.79
Price / sales · as of 2026-Q1
- Free cash flow yield
- 10%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.4%
- Growth the price implies
- −3.8%
Growth the price implies · The price pays for −3.8% free cash flow growth a year for a decade; revenue has grown +37% a year over the last three.
Details›
- Price / book2026-Q1
- 2.95
- EV / EBIT2026-Q1
- 13.2
- EV / sales2026-Q1
- 1.77
- Healthcare median P/E362 names
- 29.9
- Drug Manufacturers - Specialty & Generic median P/E32 names
- 24.3
- Free cash flow, trailing twelve months
- $191M
- Market capitalisation
- $1.89B
- 3-year revenue growth
- +37%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #13 of 29 by Smart Score